Missing Links? Citation Matrix | Graphs | Glossary HistCite Guide About |
Nodes: 1975,
Authors: 5409,
Journals: 512,
Outer References: 13295,
Words: 3300
Collection span: 1980 - 2004
View: Overview. Sorted by journal name.
Page 6: 1 2 3 4 5 6 7
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
---|---|---|---|---|---|
1501 | 0 | 1 | 330 1992 LANCET 339(8800):1057-1057 HAWKINS DF THALIDOMIDE FOR SYSTEMIC LUPUS-ERYTHEMATOSUS | 7 | 8 |
1502 | 2 | 2 | 331 1992 LANCET 339(8805):1362-1362 HIGGINS SP; BRADBEER CS THALIDOMIDE - A RESTRICTED ROLE | 0 | 0 |
1503 | 5 | 6 | 332 1992 LANCET 339(8805):1362-1362 CARMICHAEL AJ; KNIGHT A THALIDOMIDE - A RESTRICTED ROLE | 3 | 5 |
1504 | 4 | 12 | 412 1994 LANCET 343(8895):432-433 JAKEMAN P; SMITH WCS THALIDOMIDE IN LEPROSY REACTION | 8 | 14 |
1505 | 0 | 1 | 413 1994 LANCET 343(8900):795-796 CUTLER J THALIDOMIDE REVISITED | 4 | 5 |
1506 | 2 | 5 | 414 1994 LANCET 343(8904):1041-1041 JONES GRN THALIDOMIDE - 35 YEARS ON AND STILL DEFORMING | 4 | 5 |
1507 | 3 | 5 | 415 1994 LANCET 344(8916):196-197 TEIXEIRA F; HOJYO MT; ARENAS R; VEGA ME; CORTES R; ORTIZ A; DOMINGUEZ L THALIDOMIDE - CAN IT CONTINUE TO BE USED | 4 | 4 |
1508 | 0 | 0 | 473 1995 LANCET 346(8985):1289-1289 THOMPSON C THALIDOMIDE EFFECTIVE FOR AIDS-RELATED ORAL ULCERS | 5 | 10 |
1509 | 2 | 5 | 547 1996 LANCET 347(9006):974-974 Verberkmoes A; Boer K; Wertheim PME; Bronkhorst CM; Lange JMA Thalidomide for genital ulcer in HIV-positive woman | 4 | 9 |
1510 | 0 | 0 | 548 1996 LANCET 348(9038):1370-1370 Barnett AA FDA encourages firms to test thalidomide | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1511 | 0 | 0 | 629 1997 LANCET 349(9045):111-111 Barnett AA Company applies to market thalidomide in USA | 0 | 0 |
1512 | 0 | 1 | 630 1997 LANCET 350(9081):873-873 Ault A Thalidomide comes close to US approval | 1 | 1 |
1513 | 2 | 5 | 631 1997 LANCET 350(9089):1445-1446 Wettstein AR; Meagher AP Thalidomide in Crohn's disease | 35 | 53 |
1514 | 0 | 30 | 721 1998 LANCET 351(9110):1197-1199 Dally A Thalidomide: was the tragedy preventable? | 6 | 16 |
1515 | 1 | 5 | 722 1998 LANCET 351(9115):1591-1591 Smithells D Was the thalidomide tragedy preventable? | 0 | 0 |
1516 | 1 | 5 | 723 1998 LANCET 351(9115):1591-1591 Critchley EMR Was the thalidomide tragedy preventable? | 0 | 0 |
1517 | 0 | 0 | 724 1998 LANCET 352(9124):298-298 Ault A Thalidomide makes a return to US health care | 0 | 0 |
1518 | 5 | 5 | 725 1998 LANCET 352(9127):544-545 Stambe C; Wicks IP TNF alpha and response of treatment-resistant adult-onset Still's disease to thalidomide | 10 | 25 |
1519 | 8 | 28 | 726 1998 LANCET 352(9140):1586-1589 Wolkenstein P; Latarjet J; Roujeau JC; Duguet C; Boudeau S; Vaillant L; Maignan M; Schuhmacher MH; Milpied B; Pilorget A; Bocquet H; Brun-Buisson C; Revuz J Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis | 39 | 79 |
1520 | 4 | 5 | 837 1999 LANCET 353(9149):324-324 Klausner JD; Kaplan G; Haslett PAJ Thalidomide in toxic epidermal necrolysis | 7 | 8 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1521 | 1 | 2 | 838 1999 LANCET 353(9149):324-324 Levy R Thalidomide in toxic epidermal necrolysis | 1 | 2 |
1522 | 1 | 1 | 839 1999 LANCET 353(9163):1503-1503 Moore P Thalidomide's teratogenic mechanism starts to yield to study | 0 | 0 |
1523 | 0 | 0 | 840 1999 LANCET 354(9182):925-925 Larkin M Low-dose thalidomide seems to be effective in multiple myeloma | 9 | 14 |
1524 | 0 | 0 | 841 1999 LANCET 354(9191):1705-1705 Larkin M Thalidomide continues to look promising as an anticancer agent | 1 | 1 |
1525 | 2 | 5 | 1017 2000 LANCET 356(9229):566-567 Govindarajan R; Heaton KM; Broadwater R; Zeitlin A; Lang NP; Hauer-Jensen M Effect of thalidomide on gastrointestinal toxic effects of irinotecan | 21 | 30 |
1526 | 2 | 5 | 1942 2004 LANCET 363(9403):169-169 McBride W Health of thalidomide victims and their progeny | 0 | 0 |
1527 | 128 | 159 | 1943 2004 LANCET 363(9423):1802-1811 Franks ME; Macpherson GR; Figg WD Thalidomide | 0 | 0 |
1528 | 2 | 5 | 1944 2004 LANCET 363(9424):1911-1911 Crawford CL Does thalidomide have a role in leprosy? | 0 | 0 |
1529 | 0 | 5 | 1237 2001 LANCET ONCOLOGY 2(10):634-635 Hwu WJ; Raizer J; Panageas KS; Lis E Treatment of metastatic melanoma in the brain with temozolomide and thalidomide | 3 | 7 |
1530 | 0 | 0 | 1516 2002 LANCET ONCOLOGY 3(12):711-711 Lindsey H Thalidomide plus dexamethasone for newly diagnosed myeloma | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1531 | 0 | 0 | 1772 2003 LANCET ONCOLOGY 4(2):70-70 Bonn D Thalidomide: no benefit in myelofibrosis with myeloid metaplasia | 0 | 0 |
1532 | 0 | 0 | 1773 2003 LANCET ONCOLOGY 4(12):713-713 Habeck M Australia approves thalidomide | 0 | 0 |
1533 | 0 | 7 | 165 1985 LEPROSY REVIEW 56(1):35-39 GAD SM; SHANNON EJ; KROTOSKI WA; HASTINGS RC THALIDOMIDE INDUCES IMBALANCES IN LYMPHOCYTE-T SUB-POPULATIONS IN THE CIRCULATING BLOOD OF HEALTHY-MALES | 50 | 65 |
1534 | 3 | 13 | 166 1985 LEPROSY REVIEW 56(4):297-301 SHANNON EJ; TRUMAN RW; CHRISTY SA; BROWN LM; VADIEE R; HASTINGS RC EFFECT OF THALIDOMIDE ON INDUCTION OF ANTIBODY-SYNTHESIS IN MICE TO THE T-INDEPENDENT ANTIGEN, DNP-FICOLL | 5 | 6 |
1535 | 0 | 0 | 190 1986 LEPROSY REVIEW 57(1):76-77 LORETTI A; BARCHI E SUPPLIES OF THALIDOMIDE FOR USE IN LEPROSY | 1 | 1 |
1536 | 1 | 1 | 191 1986 LEPROSY REVIEW 57(3):273-273 NEELAMKAVIL P SUPPLIES OF THALIDOMIDE FOR USE IN LEPROSY | 1 | 3 |
1537 | 0 | 0 | 240 1988 LEPROSY REVIEW 59(2):184-185 BOURDILLON C THALIDOMIDE IN ERYTHEMA-NODOSUM LEPROSUM (ENL) | 0 | 0 |
1538 | 6 | 16 | 632 1997 LEPROSY REVIEW 68(1):61-66 Powell RJ; GardnerMedwin JMM Guideline for the clinical use and dispensing of thalidomide (Reprinted from the Postgraduate Medical Journal, vol 70, pg 901-904, 1994) | 1 | 3 |
1539 | 15 | 19 | 1018 2000 LEPROSY REVIEW 71:S117-S120 Kaplan G Potential of thalidomide and thalidomide analogues as immunomodulatory drugs in leprosy and leprosy reactions | 1 | 2 |
1540 | 0 | 0 | 1019 2000 LEPROSY REVIEW 71:S120-S120 Ottenhoff THM; Kaplan G; Gillis TP Potential of thalidomide and thalidomide analogues as immunomodulatory drugs in leprosy and leprosy reactions - Discussion | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1541 | 9 | 20 | 1774 2003 LEPROSY REVIEW 74(3):206-214 Tadesse A; Taye E; Sandoval F; Shannow EJ Thalidomide does not modify the ability of cells in leprosy patients to incorporate [H-3]-thymidine when incubated with M-leprae antigens | 0 | 0 |
1542 | 2 | 20 | 1775 2003 LEPROSY REVIEW 74(3):286-288 Pannikar V The return of thalidomide: new uses and renewed concerns | 0 | 1 |
1543 | 5 | 32 | 1776 2003 LEPROSY REVIEW 74(3):288-290 Pereira GFM On thalidomide and VMO policies | 0 | 0 |
1544 | 2 | 28 | 1777 2003 LEPROSY REVIEW 74(3):290-294 Lockwood D; Bryceson A The return of thalidomide: new uses and renewed concerns - reply | 0 | 2 |
1545 | 0 | 0 | 1778 2003 LEPROSY REVIEW 74(3):294-295 Naafs B The return of thalidomide: new uses and renewed concerns - reply | 0 | 1 |
1546 | 0 | 0 | 1238 2001 LEUKEMIA 15(3):491-491 Barlogie D; Spencer T; Tricot G; Zeldis J; Munshi N; Zangari M; Badros A; Toor A; Shaughnessy J; Morris C; Desikan R Long term follow up of 169 patients receiving a phase II trial of single agent thalidomide for advanced and refractory multiple myeloma (MM). | 0 | 0 |
1547 | 10 | 19 | 1239 2001 LEUKEMIA 15(8):1274-1276 Rajkumar SV; Dispenzieri A; Fonseca R; Lacy MQ; Geyer S; Lust JA; Kyle RA; Greipp PR; Gertz MA; Witzig TE Thalidomide for previously untreated indolent or smoldering multiple myeloma | 28 | 43 |
1548 | 7 | 22 | 1517 2002 LEUKEMIA 16(1):1-6 Strupp C; Germing U; Aivado M; Misgeld E; Haas R; Gattermann N Thalidomide for the treatment of patients with myelodysplastic syndromes | 15 | 26 |
1549 | 11 | 38 | 1518 2002 LEUKEMIA 16(9):1609-1614 Piccaluga PP; Visani G; Pileri SA; Ascani S; Grafone T; Isidori A; Malagola M; Finelli C; Martinelli G; Ricci P; Baccarani M; Tura S Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study | 8 | 13 |
1550 | 8 | 17 | 1779 2003 LEUKEMIA 17(1):41-44 Lentzsch S; LeBlanc R; Podar K; Davies F; Lin B; Hideshima T; Catley L; Stirling DI; Anderson KC Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo | 8 | 17 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1551 | 12 | 32 | 1780 2003 LEUKEMIA 17(4):775-779 Rajkumar SV; Gertz MA; Lacy MQ; Dispenzieri A; Fonseca R; Geyer SM; Iturria N; Kumar S; Lust JA; Kyle RA; Greipp PR; Witzig TE Thalidomide as initial therapy for early-stage myeloma | 12 | 19 |
1552 | 5 | 8 | 1781 2003 LEUKEMIA 17(6):1200-1202 Strupp C; Hildebrandt B; Germing U; Haas R; Gattermann N Cytogenetic response to thalidomide treatment in three patients with myelodysplastic syndrome | 0 | 1 |
1553 | 5 | 8 | 1782 2003 LEUKEMIA 17(8):1669-1670 Visani G; Mele A; Malagola M; Isidori A; Finelli C; Piccaluga PP Sequential combination of thalidomide and erythropoietin determines transfusion independence and disease control in idiopathic myelofibrosis previously insensitive to both drugs used as single agents | 1 | 1 |
1554 | 10 | 11 | 1783 2003 LEUKEMIA 17(9):1914-1915 Damaj G; Lefrere F; Delarue R; Varet B; Furman R; Hermine O Thalidomide therapy induces response in relapsed mantle cell lymphoma | 0 | 0 |
1555 | 3 | 8 | 1784 2003 LEUKEMIA 17(10):2056-2057 Dalle JH; Leblond P; Decouvelaere A; Yakoub-Agha I; Preudhomme C; Nelken B; Mazingue F Efficacy of thalidomide in a child with histiocytic sarcoma following allogeneic bone marrow tranplantation for T-ALL | 0 | 0 |
1556 | 3 | 6 | 1785 2003 LEUKEMIA 17(11):2237-2238 Mehta P; Hussein M Thalidomide as anti-inflammatory therapy for multiple myeloma | 0 | 0 |
1557 | 2 | 6 | 1786 2003 LEUKEMIA 17(11):2238-2238 Rajkumar SV; Witzig TE Thalidomide as anti-inflammatory therapy for multiple myeloma - Reply | 0 | 0 |
1558 | 11 | 40 | 1945 2004 LEUKEMIA 18(3):624-627 Kumar S; Witzig TE; Dispenzieri A; Lacy MQ; Wellik LE; Fonseca R; Lust JA; Gertz MA; Kyle RA; Greipp PR; Rajkumar SV Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma | 1 | 1 |
1559 | 27 | 54 | 1946 2004 LEUKEMIA 18(4):856-863 Garcia-Sanz R; Gonzalez-Porras JR; Hernandez JM; Polo-Zarzuela M; Sureda A; Barrenetxea C; Palomera L; Lopez R; Grande-Garcia C; Alegre A; Vargas-Pabon M; Gutierrez ON; Rodriguez JA; San Miguel JF The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma | 0 | 1 |
1560 | 8 | 17 | 1240 2001 LEUKEMIA & LYMPHOMA 42(4):683-+ Avigdor A; Raanani P; Levi I; Hardan I; Ben-Bassat I Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma | 8 | 9 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1561 | 5 | 24 | 1519 2002 LEUKEMIA & LYMPHOMA 43(1):133-137 Strupp C; Aivado M; Germing U; Gattermann N; Haas R Angioimmunoblastic lymphadenopathy (AILD) may respond to thalidomide treatment: Two case reports | 1 | 4 |
1562 | 7 | 8 | 1520 2002 LEUKEMIA & LYMPHOMA 43(2):351-354 Johnston RE; Abdalla SH Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia | 7 | 9 |
1563 | 4 | 26 | 1521 2002 LEUKEMIA & LYMPHOMA 43(2):401-406 Dmoszynska A; Bojarska-Junak A; Domanski D; Rolinski J; Hus M; Soroka-Wojtaszko M Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma | 2 | 6 |
1564 | 5 | 23 | 1522 2002 LEUKEMIA & LYMPHOMA 43(6):1267-1271 Badros A; Morris C; Zangari M; Barlogie B; Tricot G Thalidomide paradoxical effect on concomitant multiple myeloma and myelodysplasia | 3 | 3 |
1565 | 7 | 29 | 1523 2002 LEUKEMIA & LYMPHOMA 43(9):1777-1782 Coleman M; Leonard J; Lyons L; Pekle K; Nahum K; Pearse R; Niesvizky R; Michaeli J BLYD (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenstrom's macroglobulinemia | 4 | 6 |
1566 | 11 | 20 | 1524 2002 LEUKEMIA & LYMPHOMA 43(12):2301-2307 Giovanni B; Michelle E; Letizia C; Filippo B; Paolo PP; Giuseppe V; Monia M; Gabriele P; Francesca Z; Ayalew T Thalidomide in myelofibrosis with myeloid metaplasia: A pooled-analysis of individual patient data from five studies | 0 | 0 |
1567 | 13 | 57 | 1787 2003 LEUKEMIA & LYMPHOMA 44(2):291-298 Ribas C; Colleoni GWB Advances in the treatment of multiple myeloma: The role of thalidomide | 0 | 1 |
1568 | 12 | 13 | 1788 2003 LEUKEMIA & LYMPHOMA 44(6):989-991 Abdalla SH; Mahmoud S Thalidomide in relapsed or refractory multiple myeloma: How much and for how long? | 1 | 1 |
1569 | 1 | 6 | 1789 2003 LEUKEMIA & LYMPHOMA 44(6):1081-1082 Andretta C; Catalano L; Pace L; Fonti R; Annunziata G; Rotoli B 99mTc-sestaMIBI scintigraphy in thalidomide-treated refractory or relapsed multiple myeloma patients | 0 | 1 |
1570 | 26 | 38 | 1790 2003 LEUKEMIA & LYMPHOMA 44(7):1141-1146 Flowers MED; Martin PJ Evaluation of thalidomide for treatment or prevention of chronic graft-versus-host disease | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1571 | 12 | 17 | 1791 2003 LEUKEMIA & LYMPHOMA 44(7):1147-1149 Wechalekar AD; Chen CI; Sutton D; Reece D; Voralia M; Stewart AK Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma | 1 | 1 |
1572 | 19 | 36 | 1792 2003 LEUKEMIA & LYMPHOMA 44(9):1489-1493 Steins MB; Bieker R; Padro T; Kessler T; Kienast J; Berdel WE; Mesters RM Thalidomide for the treatment of acute myeloid leukemia | 0 | 0 |
1573 | 12 | 18 | 1793 2003 LEUKEMIA & LYMPHOMA 44(11):1943-1946 Kees M; Dimou G; Sillaber C; Drach J; Ackermann J; Lechner K; Gisslinger H Low dose thalidomide in patients with relapsed or refractory multiple myeloma | 0 | 0 |
1574 | 10 | 18 | 1947 2004 LEUKEMIA & LYMPHOMA 45(1):113-116 Anagnostopoulos A; Hamilos G; Zorzou MP; Grigoraki V; Anagnostou D; Dimopoulos MA Discordant response or progression in patients with myeloma treated with thalidomide-based regimens | 0 | 0 |
1575 | 4 | 13 | 1948 2004 LEUKEMIA & LYMPHOMA 45(1):179-181 Baird R; van Zyl-Smit RN; Iveson A; Duddy J; Rassam S Thalidomide is highly effective in a patient with meningeal acute myeloid leukaemia | 0 | 0 |
1576 | 14 | 20 | 1949 2004 LEUKEMIA & LYMPHOMA 45(4):735-738 Balleari E; Ghio R; Falcone A; Musto P Possible multiple myeloma dedifferentiation following thalidomide therapy: A report of four cases | 0 | 0 |
1577 | 7 | 12 | 1950 2004 LEUKEMIA & LYMPHOMA 45(8):1711-1712 Montagut C; Bosch F; Villela L; Rosinol L; Blade J Aminoglycoside-associated severe renal failure in patients with multiple myeloma treated with thalidomide | 0 | 0 |
1578 | 11 | 38 | 287 1990 LEUKEMIA RESEARCH 14(5):395-399 WOOD PMD; PROCTOR SJ THE POTENTIAL USE OF THALIDOMIDE IN THE THERAPY OF GRAFT-VERSUS-HOST DISEASE - A REVIEW OF CLINICAL AND LABORATORY INFORMATION | 17 | 26 |
1579 | 1 | 20 | 312 1991 LEUKEMIA RESEARCH 15(2-3):129-136 HATFILL SJ; FESTER ED; DEBEER DP; BOHM L INDUCTION OF MORPHOLOGICAL-DIFFERENTIATION IN THE HUMAN LEUKEMIC-CELL LINE K562 BY EXPOSURE TO THALIDOMIDE METABOLITES | 17 | 20 |
1580 | 3 | 5 | 1525 2002 LEUKEMIA RESEARCH 26(10):965-966 Tsirigotis P; Venetis E; Rontogianni D; Dervenoulas J; Kontopidou F; Apostolidis P Thalidomide in the treatment of myelodysplastic syndrome with fibrosis | 2 | 2 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1581 | 12 | 27 | 1794 2003 LEUKEMIA RESEARCH 27(10):909-914 Schey SA; Cavenagh J; Johnson R; Child JA; Oakervee H; Jones RW An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment | 2 | 3 |
1582 | 15 | 59 | 1951 2004 LEUKEMIA RESEARCH 28(4):325-332 Musto P Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives | 0 | 0 |
1583 | 1 | 41 | 1952 2004 LEUKEMIA RESEARCH 28(8):791-803 Raza A; Buonamici S; Lisak L; Tahir S; Li DL; Imran M; Chaudary NI; Pervaiz H; Gallegos JA; Alvi MI; Mumtaz M; Gezer S; Venugopal P; Reddy P; Galili N; Candoni A; Singer J; Nucifora G Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression | 0 | 0 |
1584 | 0 | 1 | 1241 2001 LIBRARY JOURNAL 126(7):126-126 Kupferberg N Dark remedy: The impact of thalidomide and its revival as a vital medicine. | 0 | 0 |
1585 | 8 | 27 | 333 1992 LIFE SCIENCES 51(26):2107-2116 NEUBERT R; NOGUEIRA AC; NEUBERT D THALIDOMIDE AND THE IMMUNE-SYSTEM .2. CHANGES IN RECEPTORS ON BLOOD-CELLS OF A HEALTHY VOLUNTEER | 32 | 38 |
1586 | 8 | 27 | 416 1994 LIFE SCIENCES 55(2):77-92 NOGUEIRA AC; NEUBERT R; HELGE H; NEUBERT D THALIDOMIDE AND THE IMMUNE-SYSTEM .3. SIMULTANEOUS UP-REGULATION AND DOWN-REGULATION OF DIFFERENT INTEGRIN RECEPTORS ON HUMAN WHITE BLOOD-CELLS | 56 | 63 |
1587 | 7 | 45 | 417 1994 LIFE SCIENCES 56(6):407-420 NEUBERT R; HELGE H; NEUBERT D THALIDOMIDE AND THE IMMUNE-SYSTEM .4. DOWN-REGULATION OF THE CD26 RECEPTOR, PROBABLY INVOLVED IN THE BINDING OF HIV COMPONENTS TO T-CELLS IN PRIMATES | 3 | 4 |
1588 | 14 | 38 | 474 1995 LIFE SCIENCES 58(4):295-316 Neubert R; Hinz N; Thiel R; Neubert D Down-regulation of adhesion receptors on cells of primate embryos as a probable mechanism of the teratogenic action of thalidomide | 3 | 7 |
1589 | 11 | 24 | 475 1995 LIFE SCIENCES 58(4):337-348 Nogueira AC; Neubert R; Felies A; JacobMuller U; Frankus E; Neubert D Thalidomide derivatives and the immune system .6. Effects of two derivatives with no obvious teratogenic potency on the pattern of integrins and other surface receptors on blood cells of marmosets | 2 | 3 |
1590 | 5 | 16 | 1020 2000 LIFE SCIENCES 66(2):133-141 Thiel R; Kastner U; Neubert R Expression of adhesion receptors on rat limb bud cells and results of treatment with a thalidomide derivative | 3 | 4 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1591 | 3 | 13 | 1021 2000 LIFE SCIENCES 67(4):457-461 Thiele A; Thormann M; Hofmann HJ; Naumann WW; Eger K; Hauschildt S A possible role of N-cadherin in thalidomide teratogenicity | 4 | 6 |
1592 | 22 | 33 | 549 1996 LUPUS 5(4):257-258 Stevens RJ The place of thalidomide in the treatment of inflammatory disease | 3 | 5 |
1593 | 3 | 10 | 842 1999 LUPUS 8(3):248-249 Rua-Figueroa I; Erausquin C; Naranjo A; Carretero-Hernandez G; Rodriguez-Lozano C; De la Rosa P Pustuloderma during cutaneous lupus treatment with thalidomide | 3 | 5 |
1594 | 29 | 42 | 1242 2001 LUPUS 10(3):188-192 Karim MY; Ruiz-Irastorza G; Khamashta MA; Hughes GRV Update on therapy - thalidomide in the treatment of lupus | 6 | 13 |
1595 | 17 | 38 | 1526 2002 LUPUS 11(2):67-70 Piette JC; Sbai A; Frances C Warning: thalidomide-related thrombotic risk potentially concerns patients with lupus | 3 | 5 |
1596 | 6 | 10 | 1795 2003 LUPUS 12(9):723-724 Tektonidou MG; Vlachoyiannopoulos PG Antiphospholipid syndrome triggered by thalidomide in a patient with discoid lupus erythematosus | 0 | 0 |
1597 | 5 | 7 | 1953 2004 LUPUS 13(6):481-482 Pagnoux C; Lutz-Zarrouk V; Michel M; Schaeffer A; Godeau B Cerebral venous thrombosis in a patient with antiphospholipid syndrome treated with thalidomide | 0 | 0 |
1598 | 5 | 6 | 633 1997 M S-MEDECINE SCIENCES 13(4):595-596 Audit CO; Aimar C Thalidomide-induced teratogenesis. | 0 | 0 |
1599 | 7 | 16 | 1022 2000 MAYO CLINIC PROCEEDINGS 75(8):842-844 Federman GL; Federman DG Recalcitrant pyoderma gangrenosum treated with thalidomide | 5 | 13 |
1600 | 10 | 28 | 1023 2000 MAYO CLINIC PROCEEDINGS 75(9):897-901 Rajkumar SV; Fonseca R; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Kyle RA; Gertz MA; Greipp PR Thalidomide in the treatment of relapsed multiple myeloma | 56 | 85 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1601 | 2 | 4 | 1527 2002 MAYO CLINIC PROCEEDINGS 77(12):1395-1395 Crawford CL Thalidomide-induced neuropathy | 1 | 1 |
1602 | 2 | 2 | 1528 2002 MAYO CLINIC PROCEEDINGS 77(12):1395-1395 Rajkumar SV; Gertz MA; Kyle RA; Greipp PR Thalidomide-induced neuropathy - In reply | 0 | 0 |
1603 | 23 | 39 | 1796 2003 MAYO CLINIC PROCEEDINGS 78(1):34-39 Kumar S; Gertz MA; Dispenzieri A; Lacy MQ; Geyer SM; Iturria NL; Fonseca R; Hayman SR; Lust JA; Kyle RA; Greipp PR; Witzig TE; Rajkumar SV Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma | 9 | 21 |
1604 | 15 | 44 | 1954 2004 MAYO CLINIC PROCEEDINGS 79(7):857-858 Silver RT Myelofibrosis: Thalidomide finds a new disease | 0 | 0 |
1605 | 12 | 22 | 1955 2004 MAYO CLINIC PROCEEDINGS 79(7):875-882 Richardson P; Schlossman R; Jagannath S; Alsina M; Desikan R; Blood E; Weller E; Mitsiades C; Hideshima T; Davies F; Doss D; Freeman A; Bosch J; Patin J; Knight R; Zeldis J; Dalton W; Anderson K Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: Results of an open-label Multicenter phase 2 study of efficacy, toxicity, and biological activity | 1 | 1 |
1606 | 21 | 42 | 1956 2004 MAYO CLINIC PROCEEDINGS 79(7):883-889 Mesa RA; Elliott MA; Schroeder G; Tefferi A Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia | 1 | 1 |
1607 | 50 | 83 | 1957 2004 MAYO CLINIC PROCEEDINGS 79(7):899-903 Rajkumar SV Thalidomide: Tragic past and promising future | 0 | 0 |
1608 | 1 | 36 | 90 1983 MEDICAL HYPOTHESES 10(4):437-443 HENDLER SS; MCCARTY MF THALIDOMIDE FOR AUTOIMMUNE-DISEASE | 13 | 14 |
1609 | 21 | 64 | 263 1989 MEDICAL HYPOTHESES 30(2):105-109 GUNZLER V THALIDOMIDE - A THERAPY FOR THE IMMUNOLOGICAL CONSEQUENCES OF HIV INFECTION | 4 | 6 |
1610 | 21 | 108 | 634 1997 MEDICAL HYPOTHESES 49(2):123-131 McCarty MF Thalidomide may impede cell migration in primates by down-regulating integrin beta-chains: Potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis | 17 | 31 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1611 | 13 | 66 | 727 1998 MEDICAL HYPOTHESES 50(4):313-318 Argiles JM; Carbo N; Lopez-Soriano FJ Was tumour necrosis factor-alpha responsible for the fetal malformations associated with thalidomide in the early 1960s? | 11 | 12 |
1612 | 3 | 14 | 843 1999 MEDICAL HYPOTHESES 53(1):76-77 Sastry PSRK Inhibition of TNF-alpha synthesis with thalidomide for prevention of acute exacerbations and altering the natural history of multiple sclerosis | 5 | 7 |
1613 | 1 | 11 | 1797 2003 MEDICAL HYPOTHESES 60(4):513-514 Namazi MR The potential efficacy of thalidomide in the treatment of recalcitrant alopecia areata | 0 | 0 |
1614 | 2 | 7 | 288 1990 MEDICAL JOURNAL OF AUSTRALIA 152(3):148-149 BROWN MA; FARRELL C; NEWTON P; CHILD RP THALIDOMIDE, PREGNANCY AND RENAL-FAILURE | 0 | 0 |
1615 | 2 | 4 | 289 1990 MEDICAL JOURNAL OF AUSTRALIA 152(7):382-383 GEORGHIOU PR; KEMP RJ HIV-ASSOCIATED ESOPHAGEAL ULCERS TREATED WITH THALIDOMIDE | 6 | 9 |
1616 | 1 | 6 | 1529 2002 MEDICAL JOURNAL OF AUSTRALIA 177(5):278-278 McBride W Thalidomide and cancer | 1 | 1 |
1617 | 1 | 2 | 1798 2003 MEDICAL JOURNAL OF AUSTRALIA 178(8):413-413 Elwood JM Thalidomide and cancer? | 0 | 0 |
1618 | 0 | 2 | 1958 2004 MEDICAL JOURNAL OF AUSTRALIA 180(4):199-200 Crawford CL Licensing thalidomide in Australia | 0 | 0 |
1619 | 0 | 3 | 1959 2004 MEDICAL JOURNAL OF AUSTRALIA 180(4):200-200 Tattersall MHN Licensing thalidomide in Australia - Reply | 0 | 0 |
1620 | 5 | 5 | 1960 2004 MEDICAL JOURNAL OF AUSTRALIA 180(7):366-367 Coutsouvelis J; Corallo CE Thalidomide-induced bradycardia and its management | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1621 | 0 | 0 | 728 1998 MEDICAL LETTER ON DRUGS AND THERAPEUTICS 40(1038):103-104 [Anon] Thalidomide | 1 | 0 |
1622 | 7 | 17 | 1530 2002 MEDICAL ONCOLOGY 19(2):79-86 Merup M; Kutti J; Birgergard G; Mauritzson N; Bjorkholm M; Markevarn B; Malm C; Westin J; Palmblad J; Samuelsson J; Swedish Natl Study Grp Chronic Mye Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia | 4 | 5 |
1623 | 9 | 23 | 1531 2002 MEDICAL ONCOLOGY 19(4):219-226 Srkalovic G; Elson P; Trebisky B; Karam MA; Hussein MA Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma | 1 | 2 |
1624 | 5 | 25 | 1799 2003 MEDICAL ONCOLOGY 20(4):397-401 Fraiman G; Ganti AK; Potti A; Mehdi S Angiosarcoma of the small intestine - Possible role for thalidomide? | 0 | 0 |
1625 | 0 | 0 | 264 1989 MEDICINA CLINICA 92(15):571-571 CODINA C THALIDOMIDE 1989 | 1 | 1 |
1626 | 0 | 0 | 290 1990 MEDICINA CLINICA 94(16):638-639 BERNARDO P; ARRIZABALAGA J; IRIBARREN JA; GARDE C EFFECTIVENESS OF THALIDOMIDE IN NONSPECIFIC ESOPHAGEAL ULCERS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY SYNDROME | 3 | 4 |
1627 | 0 | 0 | 313 1991 MEDICINA CLINICA 97(2):79-79 TERCEDOR J; ORTEGO N; RODENAS JM; HERNANDEZ J TREATMENT OF RECURRENT APHTHAE WITH THALIDOMIDE IN PATIENTS WITH ACQUIRED-IMMUNODEFICIENCY-SYNDROME | 1 | 1 |
1628 | 6 | 10 | 368 1993 MEDICINA CLINICA 100(14):557-557 GARCIAALBEA E; CABRERA F; TEJEIRO J; JIMENEZJIMENEZ FJ MIGRAINE AND THALIDOMIDE | 0 | 0 |
1629 | 3 | 10 | 369 1993 MEDICINA CLINICA 101(4):158-158 PIZARRO A; PINILLA J; GARCIATOBARUELA A THERAPY WITH THALIDOMIDE AND TUMOR-NECROSIS-FACTOR-ALPHA PRODUCTION | 0 | 1 |
1630 | 7 | 10 | 1961 2004 MEDICINA CLINICA 122(15):595-596 Cistero B; Sala M; Soler A; Garcia N Thalidomide in the treatment of recurrent plasmocitomas in an HIV-infected patient | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1631 | 0 | 0 | 192 1986 MEDICINA-BUENOS AIRES 46(5):528-528 BOTTASSO OA; MORINI JC; REGGIARDO Z ANTIBODIES AGAINST BCG GLYCOLIPIDS IN LEPROMATOUS PATIENTS TREATED WITH THALIDOMIDE OR LEPROUS KNOTTED ERYTHEMA | 0 | 0 |
1632 | 4 | 10 | 1024 2000 MEDICINA-BUENOS AIRES 60:61-65 Politi PM Thalidomide. Clinical trials in cancer. | 1 | 1 |
1633 | 10 | 32 | 1962 2004 MELANOMA RESEARCH 14(1):57-62 Pawlak WZ; Legha SS Phase II study of thalidomide in patients with metastatic melanoma | 0 | 0 |
1634 | 2 | 19 | 729 1998 METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY 20(9):739-742 Guinan P; Shaw M; Mirochnik Y; Slobodskoy L; Ray V; Rubenstein M Paclitaxel is more effective than thalidomide in inhibiting LNCaP tumor growth in a prostate cancer model | 2 | 5 |
1635 | 4 | 38 | 1532 2002 MICROBES AND INFECTION 4(11):1193-1202 Teo SK; Resztak KE; Scheffler MA; Kook KA; Zeldis JB; Stirling DI; Thomas SD Thalidomide in the treatment of leprosy | 8 | 10 |
1636 | 6 | 23 | 476 1995 MICROBIAL PATHOGENESIS 19(4):245-255 BURROUGHS MH; TSENOVABERKOVA L; SOKOL K; OSSIG J; TUOMANEN E; KAPLAN G EFFECT OF THALIDOMIDE ON THE INFLAMMATORY RESPONSE IN CEREBROSPINAL-FLUID IN EXPERIMENTAL BACTERIAL-MENINGITIS | 10 | 19 |
1637 | 8 | 15 | 1963 2004 MICROCHEMICAL JOURNAL 77(1):1-7 Cardoso CE; Martins ROR; Aucelio RQ Evaluation of a spectrofluorimetric method for the selective determination of thalidomide in pharmaceutical tablets, urine and blood serum | 0 | 0 |
1638 | 2 | 30 | 418 1994 MIKROCHIMICA ACTA 117(1-2):75-85 AUCELIO RQ; CAMPIGLIA AD PHARMACEUTICAL FORMULATION ANALYSIS OF THALIDOMIDE BY SOLID-SURFACE ROOM-TEMPERATURE PHOSPHORIMETRY | 1 | 10 |
1639 | 11 | 35 | 370 1993 MOLECULAR AND CELLULAR BIOCHEMISTRY 129(2):195-200 WEGLICKI WB; STAFFORD RE; DICKENS BF; MAK IT; CASSIDY MM; PHILLIPS TM INHIBITION OF TUMOR-NECROSIS-FACTOR-ALPHA BY THALIDOMIDE IN MAGNESIUM-DEFICIENCY | 4 | 9 |
1640 | 0 | 0 | 477 1995 MOLECULAR BIOLOGY OF THE CELL 6:1195-1195 DESESSO JM; HARRIS SB; SCIALLI AR; GOERINGER GC EARLY MICROSCOPIC OBSERVATIONS OF THALIDOMIDE-INDUCED LIMB DEFECTS IN NEW-ZEALAND WHITE-RABBITS | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1641 | 0 | 0 | 730 1998 MOLECULAR BIOLOGY OF THE CELL 9:200A-200A Wilson K; Lancaster T; Boyd M; Taylor LD Inhibition of cell-cell contacts in T lymphoblastic cells during exposure to thalidomide. | 0 | 0 |
1642 | 0 | 0 | 844 1999 MOLECULAR BIOLOGY OF THE CELL 10:75A-75A Taylor LD; Settles B; Wilson K; Mack C Investigation of the inhibition of cell adhesion by the Anti-TNF-alpha agent thalidomide utilizing in vitro fluorescence-based assays. | 0 | 0 |
1643 | 0 | 0 | 1025 2000 MOLECULAR BIOLOGY OF THE CELL 11:112A-112A Stevenson AN; Odoms S; Ezell T; Valentine S; Taylor L Does thalidomide reduce inflammation by altering cell adhesion molecule expression and cell-cell contacts on CEM cells? | 0 | 0 |
1644 | 0 | 0 | 1026 2000 MOLECULAR BIOLOGY OF THE CELL 11:452A-452A Ezell TN; Odoms S; Davis M; Taylor L Human T leukemic cells exhibit biochemical changes consistent with apoptosis after treatment with tumor necrosis factor alpha and thalidomide. | 0 | 0 |
1645 | 0 | 0 | 1243 2001 MOLECULAR BIOLOGY OF THE CELL 12:23A-23A Ezell TN Apoptotic cell death induced by low doses of the tumor necrosis alpha inhibitor, thalidomide in human T leukemic cells | 0 | 0 |
1646 | 4 | 18 | 478 1995 MOLECULAR MEDICINE 1(4):384-397 TRAMONTANA JM; UTAIPAT U; MOLLOY A; AKARASEWI P; BURROUGHS M; MAKONKAWKEYOON S; JOHNSON B; KLAUSNER JD; ROM W; KAPLAN G THALIDOMIDE TREATMENT REDUCES TUMOR-NECROSIS-FACTOR-ALPHA PRODUCTION AND ENHANCES WEIGHT-GAIN IN PATIENTS WITH PULMONARY TUBERCULOSIS | 60 | 131 |
1647 | 6 | 21 | 550 1996 MOLECULAR MEDICINE 2(4):506-515 Corral LG; Muller GW; Moreira AL; Chen YX; Wu MD; Stirling D; Kaplan G Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity | 44 | 63 |
1648 | 5 | 5 | 479 1995 MOLECULAR MEDICINE TODAY 1(5):210-210 STEWART A IS THALIDOMIDE A MUTAGEN | 0 | 0 |
1649 | 12 | 35 | 1800 2003 MOLECULAR PHARMACOLOGY 64(2):415-420 Drucker L; Uziel O; Tohami T; Shapiro H; Radnay J; Yarkoni S; Lahav M; Lishner M Thalidomide down-regulates transcript levels of GC-rich promoter genes in multiple myeloma | 0 | 1 |
1650 | 21 | 45 | 1964 2004 MOLECULES AND CELLS 17(2):210-216 Kim YS; Kim JS; Jung HC; Song IS The effects of thalidomide on the stimulation of NF-kappa B activity and TNF-alpha production by lipopolysaccharide in a human colonic epithelial cell line | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1651 | 1 | 14 | 124 1984 MUSCLE & NERVE 7(5):362-368 SCHWAB BW; AREZZO JC; PALDINO AM; FLOHE L; MATTHIESSEN T; SPENCER PS RABBIT SURAL NERVE RESPONSES TO CHRONIC TREATMENT WITH THALIDOMIDE AND SUPIDIMIDE | 4 | 6 |
1652 | 6 | 41 | 193 1986 MUSCLE & NERVE 9(9):837-844 LAGUENY A; ROMMEL A; VIGNOLLY B; TAIEB A; VENDEAUDBUSQUET M; DOUTRE MS; JULIEN J THALIDOMIDE NEUROPATHY - AN ELECTROPHYSIOLOGIC STUDY | 21 | 28 |
1653 | 4 | 5 | 1027 2000 MUSCLE & NERVE 23(8):1301-1302 Rao DG; Kane NM; Oware A Thalidomide neuropathy: Role of F-wave monitoring | 5 | 5 |
1654 | 13 | 29 | 1244 2001 MUSCLE & NERVE 24(8):1050-1057 Molloy FM; Floeter MK; Syed NA; Sandbrink F; Culcea E; Steinberg SM; Dahut W; Pluda J; Kruger EA; Reed E; Figg WD Thalidomide neuropathy in patients treated for metastatic prostate cancer | 12 | 17 |
1655 | 8 | 59 | 635 1997 MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS 396(1-2):45-64 Ashby J; Tinwell H; Callander RD; Kimber I; Clay P; Galloway SM; Hill RB; Greenwood SK; Gaulden ME; Ferguson MJ; Vogel E; Nivard M; Parry JM; Williamson J Thalidomide: lack of mutagenic activity across phyla and genetic endpoints | 12 | 14 |
1656 | 23 | 79 | 845 1999 MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS 425(1):153-167 Zhu XY; Zhang YP; Klopman G; Rosenkranz HS Thalidomide and metabolites: indications of the absence of 'genotoxic' carcinogenic potentials | 3 | 3 |
1657 | 92 | 148 | 1028 2000 NATIONAL MEDICAL JOURNAL OF INDIA 13(3):132-141 Grover JK; Vats V; Gopalakrishna R; Ramam M Thalidomide: A re-look | 2 | 3 |
1658 | 0 | 0 | 241 1988 NATURE 336(6195):101-101 EWING T THALIDOMIDE SCIENTIST GUILTY OF FRAUD SAYS COMMITTEE | 0 | 2 |
1659 | 4 | 11 | 480 1995 NATURE 375(6531):453-453 ASHBY J; TINWELL H IS THALIDOMIDE MUTAGENIC | 7 | 11 |
1660 | 3 | 9 | 636 1997 NATURE 385(6614):303-304 Wnendt S; Zwingenberger K Thalidomide's chirality | 9 | 16 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1661 | 2 | 5 | 637 1997 NATURE 389(6647):118-118 Ashby J Thalidomide is not a mutagen | 3 | 4 |
1662 | 2 | 9 | 731 1998 NATURE 396(6709):322-323 Tabin CJ A developmental model for thalidomide defects | 9 | 21 |
1663 | 4 | 11 | 846 1999 NATURE 400(6743):419-420 Neubert R; Merker HT; Neubert D Developmental model for thalidomide action | 3 | 4 |
1664 | 2 | 12 | 847 1999 NATURE 400(6743):420-420 Tabin CJ Developmental model for thalidomide action - Reply | 0 | 0 |
1665 | 0 | 1 | 1245 2001 NATURE 410(6827):411-412 Dormandy T Dark remedy: The impact of thalidomide and its revival as a vital medicine | 0 | 0 |
1666 | 0 | 0 | 638 1997 NATURE BIOTECHNOLOGY 15(11):1238-1239 Brower V Thalidomide checks might have saved Redux | 0 | 1 |
1667 | 0 | 0 | 639 1997 NATURE BIOTECHNOLOGY 15(12):1238-1239 Brower V Thalidomide checks might have saved Redux | 0 | 0 |
1668 | 0 | 0 | 732 1998 NATURE BIOTECHNOLOGY 16(8):695-695 [Anon] The problem with thalidomide's new incarnation | 0 | 0 |
1669 | 0 | 0 | 481 1995 NATURE MEDICINE 1(12):1230-1230 GERSHON D FINDING NEW USES FOR THALIDOMIDE | 3 | 5 |
1670 | 4 | 5 | 551 1996 NATURE MEDICINE 2(2):132-132 Crawford CL Thalidomide neuropathy | 1 | 1 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1671 | 0 | 0 | 640 1997 NATURE MEDICINE 3(1):8-8 Cimons M Thalidomide resurfaces for FDA consideration | 1 | 1 |
1672 | 5 | 11 | 848 1999 NATURE MEDICINE 5(5):489-490 Hales BF Thalidomide on the comeback trail | 30 | 32 |
1673 | 10 | 25 | 849 1999 NATURE MEDICINE 5(5):582-585 Parman T; Wiley MJ; Wells PG Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity | 65 | 111 |
1674 | 1 | 3 | 850 1999 NATURE MEDICINE 5(8):853-853 Guenzler V Mechanisms of thalidomide teratogenicity | 2 | 3 |
1675 | 39 | 57 | 1965 2004 NATURE REVIEWS CANCER 4(4):314-322 Bartlett JB; Dredge K; Dalgleish AG Timeline - The evolution of thalidomide and its IMiD derivatives as anticancer agents | 2 | 2 |
1676 | 1 | 10 | 49 1982 NATURWISSENSCHAFTEN 69(4):191-192 KOCHERBECKER U; KOCHER W; OCKENFELS H TERATOGENIC ACTIVITY OF A HYDROLYTIC THALIDOMIDE METABOLITE IN MICE | 3 | 4 |
1677 | 0 | 0 | 641 1997 NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 355(4):545-545 Stahl W; Nicolai S; Sies H Stimulation of gap junctional communication by thalidomide and thalidomide analogs in human skin fibroblasts | 0 | 0 |
1678 | 6 | 29 | 642 1997 NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 356(5):529-535 Dunzendorfer S; Schratzberger P; Reinisch N; Kahler CM; Wiedermann CJ Effects of thalidomide on neutrophil respiratory burst, chemotaxis, and transmigration of cytokine-and endotoxin-activated endothelium | 17 | 23 |
1679 | 0 | 0 | 733 1998 NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 357(4):R119-R119 Thiel R; Klug S Adhesion receptors on rat limb bud cells after treatment with a thalidomide derivative | 0 | 0 |
1680 | 0 | 0 | 734 1998 NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 358(1):R479-R479 Bignone IM; Papale RM; Seoane M; Bazerque PM Thalidomide - New trends for therapeutical use | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1681 | 2 | 23 | 419 1994 NEPHRON 67(3):270-273 SILVA SRB; VIANA PCF; LUGON NV; HOETTE M; RUZANY F; LUGON JR THALIDOMIDE FOR THE TREATMENT OF UREMIC PRURITUS - A CROSSOVER RANDOMIZED DOUBLE-BLIND TRIAL | 20 | 43 |
1682 | 11 | 21 | 1246 2001 NETHERLANDS JOURNAL OF MEDICINE 59(2):45-49 van de Poel MHW; Pasman PC; Schouten HC The use of thalidomide in chronic refractory graft versus host disease | 1 | 3 |
1683 | 0 | 7 | 314 1991 NEURO-OPHTHALMOLOGY 11(1):29-32 HUYGEN PLM; VANRIJN PM; VERHAGEN WIM; CREMERS CWRJ; THEUNISSEN EJJM SUBCORTICAL OPTOKINETIC RESPONSE IN A CASE OF THALIDOMIDE FETOPATHY | 0 | 1 |
1684 | 0 | 0 | 1533 2002 NEUROBIOLOGY OF AGING 23(1):S93-S93 Burke W; Bohac D; Cotter R; Zheng JL; Potter J; Gendelman H A 26 week double blind, placebo-controlled study of the efficacy of thalidomide in the treatment of Alzheimer's disease | 0 | 0 |
1685 | 0 | 0 | 482 1995 NEUROLOGY 45(4):A168-A168 CLAVELOU P; COLAMARINO R; DINCAN M; DEFFOND D; TOURNILHAC M; SOUTEYRAND P THALIDOMIDE-RELATED NEUROPATHY - A PROSPECTIVE, CLINICAL, ELECTROMYOGRAPHIC TRIAL | 1 | 1 |
1686 | 0 | 0 | 552 1996 NEUROLOGY 46(2):3015-3015 Openshaw H; Slatkin NE; Parker P Thalidomide neuropathy in bone marrow transplantation | 0 | 0 |
1687 | 0 | 0 | 553 1996 NEUROLOGY 46(2):27003-27003 Chaudhry V; Cornblath D; Corse A; Freimer M; SimmonsOBrien E; Vogelsang G Thalidomide-induced neuropathy: Clinical and electrophysiological features | 0 | 0 |
1688 | 0 | 0 | 735 1998 NEUROLOGY 50(4):A208-A208 Poncelet AN; Maurer TA; Wu ZQ; Ng J; Badger J; Berger TG Peripheral neuropathy in HIV-infected patients with prurigo nodularis treated with thalidomide: Clinical and electrophysiologic features | 0 | 0 |
1689 | 0 | 0 | 736 1998 NEUROLOGY 50(4):A383-A384 Frennier JM; Abrey LE; Haimovitz-Friedman A; McLoughlin M; Rosenfeld MR Does thalidomide have a role in glioma angiogenesis? | 0 | 0 |
1690 | 0 | 0 | 851 1999 NEUROLOGY 52(6):A424-A425 Li HW; Zhu LX; Karpati G; Nalbantoglu J Effect of thalidomide on growth of experimental intracerebral gliomas | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1691 | 0 | 0 | 1029 2000 NEUROLOGY 54(7):A12-A13 Gupta A; Cohen BH; Ruggieri P; Packer RJ; Phillips P A phase I study of thalidomide for the treatment of plexiform neurofibroma in patients with neurofibromatosis 1 (NF1) | 0 | 0 |
1692 | 0 | 0 | 1247 2001 NEUROLOGY 56(8):A208-A209 Khella SL; Souayah N; AMDATS Study Grp Thalidomide polyneuropathy: A prospective double-masked placebo-controlled study in an elderly population with age-related macular degeneration | 0 | 0 |
1693 | 13 | 29 | 1534 2002 NEUROLOGY 59(12):1872-1875 Chaudhry V; Cornblath DR; Corse A; Freimer M; Simmons-O'Brien E; Vogelsang G Thalidomide-induced neuropathy | 7 | 9 |
1694 | 6 | 10 | 1801 2003 NEUROLOGY 60(1):130-132 Gupta A; Cohen BH; Ruggieri P; Packer RJ; Phillips PC Phase I study of thalidomide for the treatment of plexiform neurofibroma in neurofibromatosis 1 | 1 | 4 |
1695 | 3 | 7 | 1802 2003 NEUROLOGY 60(5):877-878 Giannini F; Volpi N; Rossi S; Passero S; Fimiani M; Cerase A Thalidomide-induced neuropathy: a ganglionopathy? | 3 | 3 |
1696 | 15 | 16 | 1966 2004 NEUROLOGY 62(12):2158-2159 Apfel SC; Zochodne DW Thalidomide neuropathy - Too much or too long? | 0 | 0 |
1697 | 7 | 10 | 1967 2004 NEUROLOGY 62(12):2288-2290 Briani C; Zara G; Rondinone R; Della Libera S; Ermani M; Ruggero S; Ghirardello A; Zampieri S; Doria A Thalidomide neurotoxicity - Prospective study in patients with lupus erythematosus | 1 | 1 |
1698 | 7 | 10 | 1968 2004 NEUROLOGY 62(12):2291-2293 Cavaletti G; Beronio A; Reni L; Ghiglione E; Schenone A; Briani C; Zara G; Cocito D; Isoardo G; Ciaramitaro P; Plasmati R; Pastorelli F; Frigo M; Piatti M; Carpo M Thalidomide sensory neurotoxicity - A clinical and neurophysiologic study | 1 | 1 |
1699 | 0 | 0 | 554 1996 NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY 22(5):456-456 Chakrabarty A; Bridges LR Cerebral malformation in a patient with thalidomide related phocomelia | 0 | 0 |
1700 | 5 | 25 | 555 1996 NEUROREPORT 7(12):1881-1886 Kanbayashi T; Nishino S; Tafti M; Hishikawa Y; Dement WC; Mignot E Thalidomide, a hypnotic with immune modulating properties, increases cataplexy in canine narcolepsy | 1 | 6 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1701 | 3 | 29 | 643 1997 NEUROSCIENCE LETTERS 234(2-3):123-126 Boireau A; Bordier F; Dubedat P; Peny C; Imperato A Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice | 0 | 9 |
1702 | 1 | 26 | 1248 2001 NEUROTOXICOLOGY AND TERATOLOGY 23(3):255-264 Vorhees CV; Weisenburger WP; Minck DR Neurobehavioral teratogenic effects of thalidomide in rats | 1 | 3 |
1703 | 8 | 21 | 334 1992 NEW ENGLAND JOURNAL OF MEDICINE 326(16):1055-1058 VOGELSANG GB; FARMER ER; HESS AD; ALTAMONTE V; BESCHORNER WE; JABS DA; CORIO RL; LEVIN LS; COLVIN OM; WINGARD JR; SANTOS GW THALIDOMIDE FOR THE TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE | 166 | 253 |
1704 | 6 | 9 | 335 1992 NEW ENGLAND JOURNAL OF MEDICINE 327(3):208-209 RYAN J; COLMAN J; PEDERSEN J; BENSON E THALIDOMIDE TO TREAT ESOPHAGEAL ULCER IN AIDS | 24 | 33 |
1705 | 1 | 2 | 336 1992 NEW ENGLAND JOURNAL OF MEDICINE 327(10):735-735 VOGELSANG GB THALIDOMIDE NEUROPATHY - REPLY | 2 | 2 |
1706 | 4 | 5 | 337 1992 NEW ENGLAND JOURNAL OF MEDICINE 327(10):735-735 CRAWFORD CL THALIDOMIDE NEUROPATHY | 5 | 6 |
1707 | 21 | 44 | 644 1997 NEW ENGLAND JOURNAL OF MEDICINE 336(21):1487-1493 Jacobson JM; Greenspan JS; Spritzler J; Ketter N; Fahey JL; Jackson JB; Fox L; Chernoff M; Wu AW; MacPhail LA; Vasquez GJ; Wohl DA Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection | 119 | 192 |
1708 | 3 | 3 | 645 1997 NEW ENGLAND JOURNAL OF MEDICINE 337(15):1086-1087 Birnkrant D Thalidomide for aphthous ulcers in HIV infection | 1 | 2 |
1709 | 0 | 1 | 646 1997 NEW ENGLAND JOURNAL OF MEDICINE 337(15):1087-1087 Jacobson JM; Greenspan JS; Spritzler J Thalidomide for aphthous ulcers in HIV infection - Reply | 0 | 0 |
1710 | 9 | 37 | 852 1999 NEW ENGLAND JOURNAL OF MEDICINE 341(21):1565-1571 Singhal S; Mehta J; Desikan R; Ayers D; Roberson P; Eddlemon P; Munshi N; Anaissie E; Wilson C; Dhodapkar M; Zeldis J; Barlogie B; Siegel D; Crowley J Antitumor activity of thalidomide in refractory multiple myeloma. | 293 | 558 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1711 | 8 | 17 | 853 1999 NEW ENGLAND JOURNAL OF MEDICINE 341(21):1606-1609 Raje N; Anderson K Thalidomide - A revival story. | 48 | 87 |
1712 | 1 | 1 | 1030 2000 NEW ENGLAND JOURNAL OF MEDICINE 342(5):364-364 Singhal S Antitumor activity of thalidomide in refractory multiple myeloma (vol 341, pg 1565, 1999) | 7 | 15 |
1713 | 1 | 1 | 1031 2000 NEW ENGLAND JOURNAL OF MEDICINE 342(13):975-975 Kishi Y; Oki Y; Machida U Thalidomide in multiple myeloma | 3 | 5 |
1714 | 1 | 4 | 1032 2000 NEW ENGLAND JOURNAL OF MEDICINE 342(13):975-976 Barlogie B Thalidomide in multiple myeloma - Reply | 0 | 0 |
1715 | 4 | 6 | 1033 2000 NEW ENGLAND JOURNAL OF MEDICINE 343(13):972-973 Rajkumar SV; Gertz MA; Witzig TE Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma. | 23 | 33 |
1716 | 3 | 4 | 1249 2001 NEW ENGLAND JOURNAL OF MEDICINE 344(25):1951-1952 Osman K; Comenzo R; Rajkumar SV Deep venous thrombosis and thalidomide therapy for multiple myeloma. | 46 | 59 |
1717 | 3 | 3 | 1250 2001 NEW ENGLAND JOURNAL OF MEDICINE 345(16):1214-1215 Kudva GC; Collins BT; Dunphy FR Thalidomide for malignant melanoma. | 1 | 2 |
1718 | 2 | 3 | 1803 2003 NEW ENGLAND JOURNAL OF MEDICINE 348(18):1821-1822 Morgan AE; Smith WK; Levenson JL Reversible dementia due to thalidomide therapy for multiple myeloma | 1 | 1 |
1719 | 0 | 0 | 91 1983 NEW SCIENTIST 99(1371):457-457 MACKENZIE D SECRET TESTS SAY THALIDOMIDE IS MUTAGENIC | 0 | 0 |
1720 | 0 | 1 | 92 1983 NEW SCIENTIST 100(1378):49-49 FLOHE L THALIDOMIDE | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1721 | 0 | 0 | 371 1993 NEW SCIENTIST 137(1862):6-6 DAYTON L THALIDOMIDE HERO FOUND GUILTY OF SCIENTIFIC FRAUD | 0 | 0 |
1722 | 0 | 0 | 167 1985 NEW SOCIETY 74(1196):369-371 CAUDREY A THALIDOMIDE GENERATION | 0 | 0 |
1723 | 0 | 1 | 1251 2001 NEW YORK REVIEW OF BOOKS 48(8):12-15 Horton R Dark remedy: The impact of thalidomide and its revival as a vital medicine | 0 | 0 |
1724 | 0 | 5 | 50 1982 NOUVELLE PRESSE MEDICALE 11(14):1080-1081 HAMZA M; CHAFFAI M; BENAYED H TREATMENT OF BEHCETS-DISEASE WITH THALIDOMIDE | 9 | 15 |
1725 | 4 | 11 | 1535 2002 OBSTETRICS AND GYNECOLOGY 99(1):125-128 Ances BM New concerns about thalidomide | 1 | 3 |
1726 | 3 | 31 | 1804 2003 ONCOLOGIST 8:39-45 Hussein MA Modifications to therapy for multiple myeloma: Pegylated liposomal doxorubicin in combination with vincristine, reduced-dose dexamethasone, and thalidomide | 0 | 1 |
1727 | 13 | 44 | 1805 2003 ONCOLOGY 65(3):242-249 Hsu C; Chen CN; Chen LT; Wu CY; Yang PM; Lai MY; Lee PH; Cheng AL Low-dose thalidomide treatment for advanced hepatocellular carcinoma | 2 | 5 |
1728 | 14 | 27 | 1969 2004 ONCOLOGY REPORTS 11(1):93-95 Morabito A; Fanelli M; Carillio G; Gattuso D; Sarmiento R; Gasparini G Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma | 0 | 0 |
1729 | 0 | 0 | 854 1999 ONCOLOGY-NEW YORK 13(5):744-744 [Anon] Thalidomide shows promising results in patients with multiple myeloma | 0 | 0 |
1730 | 0 | 0 | 1034 2000 ONCOLOGY-NEW YORK 14(3):452-452 [Anon] Substantial activity of thalidomide in multiple myeloma, study shows | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1731 | 0 | 0 | 1035 2000 ONCOLOGY-NEW YORK 14(4):479-479 [Anon] Thalidomide active in advanced multiple myeloma | 0 | 0 |
1732 | 0 | 0 | 1036 2000 ONCOLOGY-NEW YORK 14(7):1081-1081 [Anon] Expanded data on thalidomide in advanced myeloma | 0 | 0 |
1733 | 0 | 0 | 1037 2000 ONCOLOGY-NEW YORK 14(12):9-10 Rajkumar SV Thalidomide in hematologic and oncologic disease - Proceedings of an Investigators' Meeting - May 20, 2000, New Orleans - Introduction | 2 | 2 |
1734 | 12 | 57 | 1038 2000 ONCOLOGY-NEW YORK 14(12):11-16 Rajkumar SV Thalidomide in multiple myeloma | 9 | 17 |
1735 | 4 | 12 | 1039 2000 ONCOLOGY-NEW YORK 14(12):17-20 Eisen TG Thalidomide in solid tumors: The London experience | 11 | 15 |
1736 | 7 | 16 | 1040 2000 ONCOLOGY-NEW YORK 14(12):25-28 Hwu WJ New approaches in the treatment of metastatic melanoma: Thalidomide and temozolomide | 6 | 14 |
1737 | 2 | 8 | 1041 2000 ONCOLOGY-NEW YORK 14(12):29-32 Govindarajan R Irinotecan and thalidomide in metastatic colorectal cancer | 7 | 12 |
1738 | 7 | 18 | 1042 2000 ONCOLOGY-NEW YORK 14(12):33-36 Amato R Thalidomide for recurrent renal-cell cancer in a 40-year-old man | 2 | 2 |
1739 | 0 | 0 | 1252 2001 ONCOLOGY-NEW YORK 15(3):301-301 [Anon] Thalidomide analogs active against multiple myeloma | 0 | 0 |
1740 | 0 | 0 | 1253 2001 ONCOLOGY-NEW YORK 15(4):493-+ [Anon] Thalidomide studied in a variety of cancers and metabolic disorders | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1741 | 28 | 70 | 1254 2001 ONCOLOGY-NEW YORK 15(7):867-874 Rajkumar SV Current status of thalidomide in the treatment of cancer | 9 | 14 |
1742 | 4 | 8 | 1255 2001 ONCOLOGY-NEW YORK 15(7):877-878 Govindarajan R Current status of thalidomide in the treatment of cancer - The Rajkumar article reviewed | 0 | 0 |
1743 | 2 | 8 | 1256 2001 ONCOLOGY-NEW YORK 15(7):878-879 Hwu WJ Current status of thalidomide in the treatment of cancer - The Rajkumar article reviewed | 0 | 0 |
1744 | 1 | 1 | 1536 2002 ONCOLOGY-NEW YORK 16(1):21-22 Kurstin R Using thalidomide in a patient with epithelioid leiomyosarcoma and Osler-Weber-Rendu disease | 1 | 1 |
1745 | 18 | 28 | 1537 2002 ONCOLOGY-NEW YORK 16(1):22-24 Richardson P; Anderson K Using thalidomide in a patient with epithelioid leiomyosarcoma and Osler-Weber-Rendu disease - Drs. Paul Richardson and Kenneth Anderson respond | 0 | 0 |
1746 | 1 | 4 | 1538 2002 ONCOLOGY-NEW YORK 16(3):276-+ Phuphanich S Recurrent multicentric glioblastoma multiforme responds to thalidomide and chemotherapy | 0 | 0 |
1747 | 4 | 17 | 1539 2002 ONCOLOGY-NEW YORK 16(4):23-26 Govindarajan R Irinoteean/Thalidomide in metastatic colorectal cancer | 5 | 6 |
1748 | 3 | 5 | 1540 2002 ONCOLOGY-NEW YORK 16(9):1146-+ Leibowitz R; Tucker SJ PSA response to thalidomide in patients with advanced prostate cancer | 0 | 0 |
1749 | 14 | 24 | 1970 2004 ONKOLOGIE 27(2):150-154 Steurer M; Spizzo G; Mitterer M; Gastl G Low-dose thalidomide for multiple myeloma: Interim analysis of a compassionate use program | 0 | 0 |
1750 | 23 | 55 | 1257 2001 OPHTHALMIC RESEARCH 33(5):256-263 Baatz H; Tonessen B; Prada J; Pleyer U Thalidomide inhibits leukocyte-endothelium interaction in endotoxin-induced uveitis | 1 | 4 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1751 | 6 | 15 | 1258 2001 OPHTHALMOLOGICA 215(1):70-73 Parentin F; Da Pozzo S; Lepore L; Perissutti P Thalidomide effectiveness for bilateral chronic idiopathic anterior uveitis in a three-year-old child | 2 | 2 |
1752 | 7 | 40 | 1259 2001 OPHTHALMOLOGICA 215(4):284-289 Kaven C; Spraul CW; Zavazava N; Lang GK; Lang GE Thalidomide and prednisolone inhibit growth factor-induced human retinal pigment epithelium cell proliferation in vitro | 2 | 7 |
1753 | 53 | 61 | 1541 2002 ORAL ONCOLOGY 38(6):527-531 Porter SR; Jorge J Thalidomide: a role in oral oncology? | 0 | 1 |
1754 | 7 | 11 | 212 1987 ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS 64(3):289-292 EISENBUD L; HOROWITZ I; KAY B RECURRENT APHTHOUS STOMATITIS OF THE BEHCETS TYPE - SUCCESSFUL TREATMENT WITH THALIDOMIDE | 7 | 18 |
1755 | 10 | 20 | 647 1997 ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS 84(4):362-364 Elad S; Galili D; Garfunkel AA; Or R Thalidomide-induced perioral neuropathy | 2 | 3 |
1756 | 44 | 67 | 1806 2003 ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS 95(5):576-585 Hegarty A; Hodgson T; Porter S Thalidomide for the treatment of recalcitrant oral Crohn's disease and orofacial granulomatosis | 1 | 2 |
1757 | 16 | 39 | 855 1999 ORGANIC LETTERS 1(10):1571-1573 Takeuchi Y; Shiragami T; Kimura K; Suzuki E; Shibata N (R)- and (S)-3-fluorothalidomides: Isosteric analogues of thalidomide | 3 | 14 |
1758 | 19 | 25 | 1807 2003 ORGANIC LETTERS 5(16):2865-2867 Capitosti SM; Hansen TP; Brown ML Facile synthesis of an azido-labeled thalidomide analogue | 0 | 2 |
1759 | 3 | 13 | 856 1999 ORGANIC PROCESS RESEARCH & DEVELOPMENT 3(2):139-140 Muller GW; Konnecke WE; Smith AM; Khetani VD A concise two-step synthesis of thalidomide | 5 | 12 |
1760 | 10 | 55 | 737 1998 PAIN 74(1):83-91 Sommer C; Marziniak M; Myers RR The effect of thalidomide treatment on vascular pathology and hyperalgesia caused by chronic constriction injury of rat nerve | 5 | 55 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1761 | 8 | 38 | 1043 2000 PAIN 88(3):267-275 George A; Marziniak M; Schafers M; Toyka KV; Sommer C Thalidomide treatment in chronic constrictive neuropathy decreases endoneurial tumor necrosis factor-alpha, increases interleukin-10 and has long-term effects on spinal cord dorsal horn met-enkephalin | 4 | 21 |
1762 | 2 | 4 | 738 1998 PALLIATIVE MEDICINE 12(3):208-209 Deaner P Thalidomide for distressing night sweats in advanced malignant disease | 12 | 13 |
1763 | 1 | 2 | 1044 2000 PALLIATIVE MEDICINE 14(1):77-78 Calder K; Bruera E Thalidomide for night sweats in patients with advanced cancer | 6 | 7 |
1764 | 2 | 4 | 1045 2000 PALLIATIVE MEDICINE 14(5):429-431 Deaner PB The use of thalidomide in the management of severe sweating in patients with advanced malignancy: trial report | 0 | 1 |
1765 | 0 | 0 | 420 1994 PANMINERVA MEDICA 36(1):1-4 VOSGERAU JCB AUTOIMMUNITY IN HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION AND THE USE OF THALIDOMIDE | 3 | 3 |
1766 | 0 | 0 | 421 1994 PANMINERVA MEDICA 36(1):44-47 VOSGERAU JCB ATYPICAL HERPES SIMPLE - A SIGN OF TOXOPLASMOSIS ACTIVITY IN AIDS PATIENTS AND THE USE OF THALIDOMIDE | 0 | 1 |
1767 | 0 | 18 | 23 1981 PATHOLOGIE BIOLOGIE 29(10):601-604 FAURE M; LEJEUNE JP; GAUCHERAND M; THIVOLET J PMN LEUKOCYTES CHEMOTAXIS - INHIBITION BY THALIDOMIDE | 6 | 9 |
1768 | 10 | 41 | 1971 2004 PATHOLOGY INTERNATIONAL 54(5):285-294 Du WL; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment | 0 | 0 |
1769 | 11 | 22 | 1808 2003 PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS 33:15-18 Rodeghiero F; Elice F Thalidomide and thrombosis | 1 | 2 |
1770 | 0 | 0 | 372 1993 PEDIATRIC DERMATOLOGY 10(3):283-285 MENNI S; IMONDI D; BRANCALEONE W; CROCI S RECURRENT GIANT APHTHOUS ULCERS IN A CHILD - PROTRACTED TREATMENT WITH THALIDOMIDE | 5 | 10 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1771 | 8 | 16 | 1260 2001 PEDIATRIC DERMATOLOGY 18(2):143-145 Brik R; Shamali H; Bergman R Successful thalidomide treatment of severe infantile Behcet disease | 1 | 1 |
1772 | 10 | 14 | 556 1996 PEDIATRIC INFECTIOUS DISEASE JOURNAL 15(5):465-467 DeVincenzo JP; Burchet SK Prolonged thalidomide therapy for human immunodeficiency virus-associated recurrent severe esophageal and oral aphthous ulcers | 5 | 7 |
1773 | 1 | 26 | 1809 2003 PEDIATRIC NEUROLOGY 29(2):151-156 Marjanovic BD; Stojanov LM; Zdravkovic DS; Kravljanac RM; Djordjevic MS Rasmussen syndrome and long-term response to thalidomide | 0 | 0 |
1774 | 0 | 4 | 168 1985 PEDIATRIC RESEARCH 19(4):A324-A324 GARDNER LI; WELSHSLOAN J; CADY RB PHOCOMELIA OF LEFT LOWER LEG IN AN INFANT WHOSE MOTHER TOOK LARGE DOSES OF PYRIDOXINE (B-6) - DEJA VU OF THE THALIDOMIDE DISASTER | 0 | 0 |
1775 | 0 | 0 | 857 1999 PEDIATRIC RESEARCH 45(4):67A-67A Jakkula M; Le Cras TD; Abman SH Effects of fumagillin and thalidomide treatment on alveolarization in the developing rat lung | 0 | 4 |
1776 | 0 | 0 | 1046 2000 PEDIATRIC RESEARCH 47(4):264A-264A Hanekom W; Ganiso B; Appolis P; Hughes J; Allin R; Goddard E; Haslett P; Hussey G; Kaplan G Safety and immune effects of thalidomide in HIV-infected children | 0 | 0 |
1777 | 2 | 25 | 1542 2002 PEDIATRIC RESEARCH 52(4):576-579 Narita N; Kato M; Tazoe M; Miyazaki K; Narita M; Okado N Increased monoamine concentration in the brain and blood of fetal thalidomide-and valproic acid-exposed rat: Putative animal models for autism | 0 | 3 |
1778 | 11 | 13 | 858 1999 PEDIATRICS 103(4):art. no.-e44 Mehta P; Kedar A; Graham-Pole J; Skoda-Smith S; Wingard JR Thalidomide in children undergoing bone marrow transplantation: Series at a single institution and review of the literature | 0 | 10 |
1779 | 10 | 22 | 859 1999 PEDIATRICS 103(6):1295-1297 Shek LPC; Lee YS; Lee BW; Lehman TJA Thalidomide responsiveness in an infant with Behcet's syndrome | 10 | 16 |
1780 | 0 | 37 | 93 1983 PERSPECTIVES IN BIOLOGY AND MEDICINE 27(1):93-106 WYATT HV DID THALIDOMIDE PROMOTE POLIOMYELITIS FOLLOWING ORAL POLIOVIRUS VACCINATION IN WEST-BERLIN IN 1960 | 0 | 4 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1781 | 6 | 24 | 1543 2002 PHARMACEUTICAL RESEARCH 19(1):13-19 Goosen C; Laing TJ; du Plessis J; Goosen TC; Flynn GL Physicochemical characterization and solubility analysis of thalidomide and its N-alkyl analogs | 4 | 4 |
1782 | 3 | 21 | 1544 2002 PHARMACEUTICAL RESEARCH 19(4):434-439 Goosen C; Laing TJ; du Plessis J; Goosen TC; Lu GW; Flynn GL Percutaneous delivery of thalidomide and its N-alkyl analogs | 3 | 4 |
1783 | 10 | 18 | 1545 2002 PHARMACEUTICAL RESEARCH 19(8):1232-1235 Goosen C; Laing TJ; du Plessis J; Goosen TC; Rao TB; Flynn GL Chemical stabilities and biological activities of thalidomide and its N-alkyl analogs | 3 | 3 |
1784 | 3 | 8 | 860 1999 PHARMACOLOGY & TOXICOLOGY 85(2):103-104 Huang PHT; McBride WG; Tuman WG Interaction of thalidomide with DNA of rabbit embryos: A possible explanation for its immunosuppressant and teratogenic effects | 3 | 3 |
1785 | 0 | 0 | 1810 2003 PHARMACOPSYCHIATRY 36(5):263-264 Schuld A; Hinze-Selch D; Haack M; Dalal MA; Himmerich H; Lancel M; Pollmacher T Sleep changes following chlorpromazine, clozapine, olanzapine or thalidomide in healthy subjects - First results from a double-blind, placebocontrolled study | 0 | 0 |
1786 | 11 | 22 | 861 1999 PHARMACOTHERAPY 19(10):1177-1180 Horowitz SB; Stirling AL Thalidomide-induced toxic epidermal necrolysis | 10 | 10 |
1787 | 11 | 47 | 1546 2002 PHARMACOTHERAPY 22(8):1019-1028 Cool RM; Herrington JD Thalidomide for the treatment of relapsed and refractory multiple myeloma | 1 | 1 |
1788 | 0 | 0 | 1547 2002 PHARMACOTHERAPY 22(10):1362-1362 Ando Y; Price DK; Dahut WL; Cox MC; Reed E; Figg WD Pharmacogenetics of thalidomide: drug response, in vivo metabolism and genetic polymorphism of CYP2C19. | 0 | 0 |
1789 | 15 | 21 | 1811 2003 PHARMACOTHERAPY 23(3):315-318 Horne MK; Figg WD; Arlen P; Gulley J; Parker C; Lakhani N; Parnes H; Dahut WL Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer | 3 | 4 |
1790 | 41 | 78 | 1812 2003 PHARMACOTHERAPY 23(4):481-493 Okafor MC Thalidomide for erythema nodosum leprosum and other applications | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1791 | 0 | 9 | 373 1993 PHARMAZIE 48(2):147-148 HOFENEDER M; KREBS G; SUTTER B; KOCH HP ACUTE TOXICITY OF THALIDOMIDE, TAGLUTIMIDE AND SUPIDIMIDE IN THE YEAST-TEST | 0 | 2 |
1792 | 10 | 37 | 1813 2003 PHOTODERMATOLOGY PHOTOIMMUNOLOGY & PHOTOMEDICINE 19(6):272-280 Lu KQ; Brenneman S; Burns R; Vink A; Gaines E; Haake A; Gaspari A Thalidomide inhibits UVB-induced mouse keratinocyte apoptosis by both TNF-alpha-dependent and TNF-alpha-independent pathways | 0 | 0 |
1793 | 2 | 10 | 1261 2001 POLISH JOURNAL OF PHARMACOLOGY 53(6):709-713 Dmoszynska A; Rolinski J; Bojarska-Junak A; Manko J; Jawniak D; Walter-Croneck A; Soroka-Wojtaszko M; Hus M Influence of thalidomide on Bcl(2) expression and proangiogenic cytokine levels in short-term culture of peripheral blood and bone marrow mononuclear cells of multiple myeloma patients | 0 | 0 |
1794 | 0 | 1 | 24 1981 POLITICAL QUARTERLY 52(1):135-136 STREET H THE SUNDAY-TIMES THALIDOMIDE CASE - CONTEMPT OF COURT AND THE FREEDOM OF THE PRESS - ROSEN,M | 0 | 0 |
1795 | 15 | 43 | 422 1994 POSTGRADUATE MEDICAL JOURNAL 70(830):860-862 GARDNERMEDWIN JM; POWELL RJ THALIDOMIDE - THE WAY FORWARD | 7 | 10 |
1796 | 4 | 13 | 423 1994 POSTGRADUATE MEDICAL JOURNAL 70(830):901-904 POWELL RJ; GARDNERMEDWIN JMM GUIDELINE FOR THE CLINICAL USE AND DISPENSING OF THALIDOMIDE | 39 | 53 |
1797 | 1 | 1 | 483 1995 POSTGRADUATE MEDICAL JOURNAL 71(832):123-123 JUDGE MR; KOBZABLACK A; HAWK JLM GUIDELINES FOR THE CLINICAL USE AND DISPENSING OF THALIDOMIDE | 0 | 0 |
1798 | 66 | 77 | 1814 2003 POSTGRADUATE MEDICAL JOURNAL 79(929):127-132 Gordon JN; Goggin PM Thalidomide and its derivatives: emerging from the wilderness | 0 | 3 |
1799 | 0 | 3 | 25 1981 PRACTITIONER 225(1355):721-& QUIBELL EP THE THALIDOMIDE EMBRYOPATHY - AN ANALYSIS FROM THE UK | 9 | 13 |
1800 | 0 | 1 | 51 1982 PRAXIS DER KINDERPSYCHOLOGIE UND KINDERPSYCHIATRIE 31(6):250-250 BIERMANN G THE ADOLESCENCE OF THALIDOMIDE DAMAGED CHILDREN - GERMAN - JOCHMUS,I, SCHMIDT,GM, LOHMAR,L, LOHMAR,W | 0 | 0 |